185 related articles for article (PubMed ID: 37267439)
1. Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis.
Zarnegar-Lumley S; Alonzo TA; Gerbing RB; Othus M; Sun Z; Ries RE; Wang J; Leonti A; Kutny MA; Ostronoff F; Radich JP; Appelbaum FR; Pogosova-Agadjanyan EL; O'Dwyer K; Tallman MS; Litzow M; Atallah E; Cooper TM; Aplenc RA; Abdel-Wahab O; Gamis AS; Luger S; Erba H; Levine R; Kolb EA; Stirewalt DL; Meshinchi S; Tarlock K
Blood Adv; 2023 Oct; 7(19):5941-5953. PubMed ID: 37267439
[TBL] [Abstract][Full Text] [Related]
2. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of IDH1 and IDH2 mutations in patients with acute myeloid leukemia].
Jia ZX; Zhou M; Chao HY; Lu XZ; Zhang R; Cen L; Xiao R; Jiang NK
Zhonghua Xue Ye Xue Za Zhi; 2012 May; 33(5):397-401. PubMed ID: 22781800
[TBL] [Abstract][Full Text] [Related]
4. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of cooccurring mutations in FLT3-ITD pediatric acute myeloid leukemia.
Tarlock K; Gerbing RB; Ries RE; Smith JL; Leonti A; Huang BJ; Kirkey D; Robinson L; Peplinksi JH; Lange B; Cooper TM; Gamis AS; Kolb EA; Aplenc R; Pollard JA; Alonzo TA; Meshinchi S
Blood Adv; 2024 May; 8(9):2094-2103. PubMed ID: 38295280
[TBL] [Abstract][Full Text] [Related]
6. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
7. Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment.
Lachowiez CA; Reville PK; Kantarjian H; Jabbour E; Borthakur G; Daver N; Issa G; Furudate K; Tanaka T; Pierce S; Tang G; Patel KP; Medeiros J; Abbas HA; Haddad F; Hammond D; Short NJ; Maiti A; Yilmaz M; Sasaki K; Takahashi K; Pemmaraju N; Konopleva M; Garcia-Manero G; Ravandi F; Kadia TM; Loghavi S; DiNardo CD
Am J Hematol; 2022 Nov; 97(11):1443-1452. PubMed ID: 36054614
[TBL] [Abstract][Full Text] [Related]
8. IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation.
Yamaguchi S; Iwanaga E; Tokunaga K; Nanri T; Shimomura T; Suzushima H; Mitsuya H; Asou N
Eur J Haematol; 2014 Jun; 92(6):471-7. PubMed ID: 24443894
[TBL] [Abstract][Full Text] [Related]
9. [Clinical characteristics in adult acute myeloid leukemia with isocitrate dehydrogenase gene mutation].
Wang RX; Wu DP; Chen SN; He J; Xu Y; Wang XL; Yin J; Tian H; Tian XP; Sun AN
Zhonghua Yi Xue Za Zhi; 2013 Mar; 93(10):751-5. PubMed ID: 23755812
[TBL] [Abstract][Full Text] [Related]
10. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML.
DiNardo CD; Ravandi F; Agresta S; Konopleva M; Takahashi K; Kadia T; Routbort M; Patel KP; Mark Brandt ; Pierce S; Garcia-Manero G; Cortes J; Kantarjian H
Am J Hematol; 2015 Aug; 90(8):732-6. PubMed ID: 26016821
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
Shoukier M; Kadia T; Konopleva M; Alotaibi AS; Alfayez M; Loghavi S; Patel KP; Kanagal-Shamanna R; Cortes J; Samra B; Jabbour E; Garcia-Manero G; Takahashi K; Pierce S; Short NJ; Yilmaz M; Sasaki K; Masarova L; Pemmaraju N; Borthakur G; Kantarjian HM; Ravandi F; DiNardo CD; Daver N
Cancer; 2021 Feb; 127(3):381-390. PubMed ID: 33119202
[TBL] [Abstract][Full Text] [Related]
12. Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group.
Ho PA; Kutny MA; Alonzo TA; Gerbing RB; Joaquin J; Raimondi SC; Gamis AS; Meshinchi S
Pediatr Blood Cancer; 2011 Aug; 57(2):204-9. PubMed ID: 21504050
[TBL] [Abstract][Full Text] [Related]
13. Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study.
Ho PA; Alonzo TA; Kopecky KJ; Miller KL; Kuhn J; Zeng R; Gerbing RB; Raimondi SC; Hirsch BA; Oehler V; Hurwitz CA; Franklin JL; Gamis AS; Petersdorf SH; Anderson JE; Reaman GH; Baker LH; Willman CL; Bernstein ID; Radich JP; Appelbaum FR; Stirewalt DL; Meshinchi S
Leukemia; 2010 May; 24(5):909-13. PubMed ID: 20376086
[TBL] [Abstract][Full Text] [Related]
14. Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia.
Lu J; Chen M; Hua H; Qin W; Zhang R; Lu X; Chao H
Int J Lab Hematol; 2021 Dec; 43(6):1483-1490. PubMed ID: 34270876
[TBL] [Abstract][Full Text] [Related]
15. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.
Abbas S; Lugthart S; Kavelaars FG; Schelen A; Koenders JE; Zeilemaker A; van Putten WJ; Rijneveld AW; Löwenberg B; Valk PJ
Blood; 2010 Sep; 116(12):2122-6. PubMed ID: 20538800
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of nucleophosmin mutations and FLT3 internal tandem duplication in adult patients with cytogenetically normal acute myeloid leukemia.
Kim YK; Kim HN; Lee SR; Ahn JS; Yang DH; Lee JJ; Lee IK; Shin MG; Kim HJ
Korean J Hematol; 2010 Mar; 45(1):36-45. PubMed ID: 21120161
[TBL] [Abstract][Full Text] [Related]
17. IDH Mutations in AML Patients; A higher Association with Intermediate Risk Cytogenetics.
ElNahass YH; Badawy RH; ElRefaey FA; Nooh HA; Ibrahiem D; Nader HA; Mahmoud HK; ElMetnawy WH
Asian Pac J Cancer Prev; 2020 Mar; 21(3):721-725. PubMed ID: 32212799
[TBL] [Abstract][Full Text] [Related]
18. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients.
El Gammal MM; Ebid GT; Madney YM; Abo-Elazm OM; Kelany AK; Torra OS; Radich JP
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e281-e290. PubMed ID: 30926392
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups.
Damm F; Thol F; Hollink I; Zimmermann M; Reinhardt K; van den Heuvel-Eibrink MM; Zwaan CM; de Haas V; Creutzig U; Klusmann JH; Krauter J; Heuser M; Ganser A; Reinhardt D; Thiede C
Leukemia; 2011 Nov; 25(11):1704-10. PubMed ID: 21647152
[TBL] [Abstract][Full Text] [Related]
20. Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG.
Ho PA; Kopecky KJ; Alonzo TA; Gerbing RB; Miller KL; Kuhn J; Zeng R; Ries RE; Raimondi SC; Hirsch BA; Oehler V; Hurwitz CA; Franklin JL; Gamis AS; Petersdorf SH; Anderson JE; Godwin JE; Reaman GH; Willman CL; Bernstein ID; Radich JP; Appelbaum FR; Stirewalt DL; Meshinchi S
Blood; 2011 Oct; 118(17):4561-6. PubMed ID: 21873548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
